announced Tuesday that the Food and Drug Administration granted marketing clearance to use the Aprima Combo 2 assay to test two additional kinds of patient samples for Chlamydia trachomatis and Neisseria gonorrhea on the fully automated Tigris system.
The Aptima Combo 2 assay is cleared to detect Chlamydia infections and gonorrhea from a wide variety of sample types, the San Diego-based company said.
"This clearance adds to the comprehensive solution that Gen-Probe offers customers for sexually transmitted disease testing, and helps them maximize the value of the unique, fully automated Tigris system," the company added. "Intercepting STDs in conjunction with ThinPrep Pap Tests, or via non-invasive vaginal swabs, provides physicians two additional, convenient ways to prevent serious medical complications and avoid unnecessary healthcare costs."
This story was created through a joint venture between TheStreet.com and IRIS.